Fundraising Fox

Avicenna Biosciences

Durham, US · Founded 2020 · Delaware corporation · 1 known investors

Find your way into Avicenna Biosciences

371 people in our graph share verified history with the Avicenna Biosciences team — schools, employers, funds. One of them is your warm intro.

Mariaunlockedknows Thomas Kaiser · together at University of Oxford (overlapped)
×7knows the team · via University of Oxford
×2knows the team · via Emory University
×2knows the team · via Texas A&M University

BioCentury provides news, analysis, and data covering the biotechnology and pharmaceutical industries.

BiotechData & InfrastructureEnterprise SoftwareMedia & Entertainment

Founders & leadership

PB
Pieter BurgerinExecutivePieter Burger is Co-founder and VP of Informatics at Avicenna Biosciences, where he applies computational methods—including molecular modeling, free energy calculations, molecular dynamics, and machine learning—to drug discovery and optimization. His research focuses on understanding how data quality and representation influence the reliability of computational predictions in medicinal chemistry.
TKThomas Kaiser
Thomas KaiserinExecutiveThomas Kaiser trained in biochemistry, mathematics, organic chemistry, medicinal chemistry, artificial intelligence, and clinical medicine. He is an executive officer and director at Avicenna Biosciences, a biotechnology company developing therapeutics.

Board

CMChristopher Meldrum
Christopher MeldruminBoard directorEntrepreneur In Residence, DCVC Bio at DCVC Bio
JHJohn Hamer
John Hamerin𝕏Board directorManaging Partner, DCVC Bio at DCVC (Data Collective)
DL
Dennis LangerBoard director

Investors · 1

DCVC Bioreported · 2 sourcesPalo Alto

Reported raises · per SEC filings

Form D private placements

$17.6M disclosed across 5 rounds · 2020–2024

▶$70.7KraisedOct 2025 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Pieter BurgerExecutive Officer, Director
  • John HamerDirector
  • Dennis LangerDirector
  • Thomas KaiserExecutive Officer, Director
  • Christopher MeldrumExecutive Officer, Director
Offering amount
$70.7K
Amount sold
$70.7K
First sale
Feb 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6MraisedJul 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Pieter BurgerExecutive Officer, Director
  • Christopher MeldrumExecutive Officer, Director
  • Thomas KaiserExecutive Officer, Director
  • Dennis LangerDirector
  • John HamerDirector
Offering amount
$6M
Amount sold
$6M
First sale
Jul 2024
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6MraisedFeb 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John HamerDirector
  • Christopher MeldrumExecutive Officer, Director
  • Thomas KaiserExecutive Officer, Director
  • Pieter BurgerExecutive Officer, Director
  • Dennis LangerDirector
Offering amount
$10M
Amount sold
$6M
First sale
Nov 2023
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3MraisedDec 2022 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Dennis LangerDirector
  • John HamerDirector
  • Pieter BurgerDirector
  • Thomas KaiserExecutive Officer, Director
  • Christopher MeldrumExecutive Officer, Director
Offering amount
$6M
Amount sold
$3M
First sale
Apr 2022
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.5MraisedSep 2020 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Pieter BurgerDirector
  • Christopher MeldrumExecutive Officer, Director
  • Thomas KaiserDirector
Offering amount
$2.5M
Amount sold
$2.5M
First sale
Aug 2020
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap
Bioworld1289 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Globaldata1259 shared keywordsGlobalData provides an AI-powered intelligence platform that delivers research, market analysis, and predictive insights to enterprises across industries. The platform combines proprietary data, in-house subject matter experts, and AI tools to support critical business decisions.

Companies competing with Avicenna Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Avicenna Biosciences Secures U.S. Patent for Novel Compounds That Can Be Used in the Treatment of Neurodegenerative Diseases - BioSpacebiospace.com · Oct 2024Avicenna Introduces Machine Learning-Enhanced Medicinal Chemistry Platform to Accelerate the Last Mile of Small Molecule Drug Discoverybusinesswire.com · May 2024Durham-based biotech raises $6 million - Business North Carolinabusinessnc.com · Feb 2024Durham biotech startup Avicenna Biosciences raises $2.5M | WRAL TechWirewraltechwire.com · Sep 2020

Frequently asked questions

What does Avicenna Biosciences do?
BioCentury provides news, analysis, and data covering the biotechnology and pharmaceutical industries.
Who are Avicenna Biosciences's investors?
Avicenna Biosciences's investors include DCVC Bio.
How much funding has Avicenna Biosciences raised?
Avicenna Biosciences has disclosed $17.6M raised across 5 rounds.
Where is Avicenna Biosciences headquartered?
Avicenna Biosciences is headquartered in Durham, US.